Login to Your Account

FDA adcom documents may offer reasonable path for OIC drug class

By Marie Powers
Staff Writer

Tuesday, June 10, 2014

The FDA's Anesthetic and Analgesic Drug Products Advisory Committee (adcom) is slated to meet Wednesday to discuss the potential cardiovascular (CV) risk associated with peripherally acting opioid receptor antagonists in development to treat opioid-induced constipation (OIC).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription